The comprehensive analysis of known actionable genes in the CancerPlex℠ assay is immediately valuable for patients in selecting more effective treatments and avoiding treatments that don’t prolong life. In that way, it supports our mission saving lives
New York, NY (PRWEB) January 12, 2015
KEW’s CancerPlex assay utilizes next-generation sequencing to analyze more than 400 known cancer genes that are involved in cancer initiation and progression. The information resulting from this kind of tumor sequencing can be used directly by physicians to supplement other patient-specific information and assist in the selection of effective treatment options.
Scott Schell, CEO of the KEW group, commented, “We are absolutely delighted with the opportunity to partner with Genomic Expressions. KEW’s CancerPlex is an ideal complement to Genomic Expressions’ robust suite of sample evaluation and informatics. Our united ability to bring large-scale oncology genomic profiling to Scandinavian cancer patients represents a dramatic improvement in current diagnostic options. The CancerPlex’s test provides, in a single assay, a comprehensive evaluation of all actionable genes linked to approved therapies and ongoing clinical trials.”
Gitte Pedersen, CEO of Genomic Expression, observes, “The comprehensive analysis of known actionable genes in the CancerPlex℠ assay is immediately valuable for patients in selecting more effective treatments and avoiding treatments that don’t prolong life. In that way, it supports our mission to save lives and make health care more effective. We are excited to be entering into this collaboration.”
About the KEW Group
KEW is revolutionizing cancer care by empowering oncologists to access and apply genomic insights in order to design optimal, individualized treatment approaches for patients. KEW gives oncologists practical, action-oriented solutions by coupling comprehensive patient-specific genomic data together with evidence-based information about approved and emerging therapies to help guide treatment decisions and advance optimal patient care. KEW’s first product, CancerPlex℠, is one of the most comprehensive genetic/genomic tests available for the accurate, thorough, and timely molecular diagnosis of solid tumors. KEW Group Inc. (KEW) is a privately held oncology services company located in Cambridge, Mass.
About Genomic Expression
Genomic Expression’s mission is to save lives and to make the delivery of health care more effective. The inconvenient truth is that only one out of four cancer treatments prolong life.
Genomic Expression is developing diagnostics that use sequencing by leveraging it’s clinically applicable sample preparation and informatics technologies for Next Generation Sequencing and access to biological samples, in a novel partnership model which enables the company to create a pipeline of Next Generation Diagnostics with limited cash burn and regulatory risk, while maintaining a significant product upside.
Genomic Expression Contact
Gitte Pedersen, CEO
375 Park Avenue, Suite 2607
New York City NY 10152, USA
Phone: +(1) 646-847-9290
KEW Group Contact
Scott Schell, President and CEO
840 Memorial Drive
Cambridge, MA 02139
Phone: +(1) 617-945-7922